Willow vs Maximus: structured support vs low-cost compounded care

Willow vs Maximus answers a common choice: do you want a telehealth-first program that emphasizes progress tracking and follow-up support, or a lower-cost, direct-pay compounded semaglutide option? Early verdict: choose Willow if you need structured digital follow-up and behavioral scaffolding; choose Maximus if you prioritize a low flat rate for compounded semaglutide through telemedicine.

Explore Willow’s progress-tracking program

Side-by-side snapshot: core positioning

Willow positions its oral GLP-1 offering as a structured weight management journey with licensed clinician review, progress tracking tools, and follow-up consultations. Maximus positions itself as a low-cost telemedicine provider for compounded semaglutide, with prescriptions approved by licensed doctors and filled through trusted U.S. pharmacies at a flat rate of $132.99/month.

Five key differences that matter

1) Program model and emphasis

Willow emphasizes a programmatic approach: it frames treatment as a structured weight management journey, not merely a medication subscription, and highlights behavioral scaffolding to convert GLP-1 efficacy into sustainable outcomes. Maximus emphasizes a straightforward, low-cost direct-pay model focused on access to compounded semaglutide via telemedicine.

2) Pricing and cost structure

Willow’s starting price is listed as 299. Sources describe Willow as having higher monthly entry pricing for some plans. Maximus advertises a low flat rate at $132.99/month and mentions starting at lower amounts in some landing-page lines such as $79.99/month for certain offers; the detailed description repeatedly cites $132.99/month as a primary pricing point.

See Maximus pricing and availability

3) Medication sourcing and regulatory notes

Maximus fills prescriptions through trusted U.S. pharmacies and offers compounded medication. The evidence states that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Willow’s evidence also notes that compounded medications, when offered, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Willow requires a licensed clinician to determine medical appropriateness.

4) Clinical access and follow-up

Both use telemedicine and licensed clinicians. Willow highlights licensed telehealth teams plus progress tracking tools and follow-up consultations built into a digital workflow. Maximus highlights convenient telemedicine access with prescriptions approved by licensed doctors and no in-person clinic visits; it also notes eligibility across most states with some exceptions and a refund if not approved for treatment.

5) Target user and track record

Willow is best for users who want structured digital follow-up. Maximus is described as best for online GLP-1 weight loss care at a low cost, but the evidence notes a smaller patient base and limited public reviews compared with larger competitors.

Comparison table

Practical considerations before choosing

If you value structured behavioral support, progress tracking, and follow-up consultations as part of treatment, the captured evidence identifies Willow as the better fit. If you prioritize a lower monthly outlay and direct-pay access to compounded semaglutide prescribed and shipped through U.S. pharmacies, Maximus presents a low-cost telemedicine option at $132.99/month in the captured materials.

Check Willow program details

Regulatory and safety reminders

Both providers note that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Willow specifies that treatment is available only when a licensed clinician determines it is medically appropriate. Maximus states prescriptions are approved by licensed doctors and filled through trusted U.S. pharmacies, and that availability excludes Mississippi per captured landing-page evidence.

Start Willow’s intake to confirm medical appropriateness

Conclusion and recommendation: Willow vs Maximus

Willow vs Maximus boils down to support versus price. Willow emphasizes structured follow-up, progress tracking, and a licensed telehealth workflow and is best for users who want digital behavioral scaffolding. Maximus offers a straightforward, low flat-rate compounded semaglutide program via telemedicine at $132.99/month and is best for cost-driven patients seeking access to compounded semaglutide through U.S. pharmacies.

Choose Willow if you want structured digital follow-up, progress tracking tools, and follow-up consultations integrated into a telehealth-first weight management journey where a licensed clinician determines medical appropriateness.

Choose Maximus if you want a lower-cost, direct-pay telemedicine option for compounded semaglutide with prescriptions approved by licensed doctors and filled through trusted U.S. pharmacies at a flat rate cited as $132.99/month.

Get Maximus telemedicine access